Boehringer Ingelheim to present early clinical evidence of innate immune modulation and anti-tumor activity via SIRPα blockade in two ongoing trials at ASCO 2025
Notified -
Globe Newswire23-05-2025, 04:05
Founder Group Limited Receives NASDAQ Notification Regarding Minimum Publicly Held Shares Deficiency 21-02-2026, 04:30